





{"id":49,"date":"2025-04-16T07:35:38","date_gmt":"2025-04-16T05:35:38","guid":{"rendered":"https:\/\/www.degro.org\/mammakarzinom\/?page_id=49"},"modified":"2026-07-09T09:48:41","modified_gmt":"2026-07-09T07:48:41","slug":"leitlinien-positionspapiere","status":"publish","type":"page","link":"https:\/\/www.degro.org\/mammakarzinom\/leitlinien-positionspapiere\/","title":{"rendered":"Leitlinien\/Positionspapiere"},"content":{"rendered":"<div id=\"pl-49\"  class=\"panel-layout\" ><div id=\"pg-49-0\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-49-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-49-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<h4>\u00a0<\/h4>\n<ul>\n<li>\n<h4>2013 DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-013-0437-8\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2014 DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-013-0502-3\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2014 DEGRO practical guidelines: radiotherapy of breast cancer III\u2014radiotherapy of the lymphatic pathways. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-013-0543-7\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2014 DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-014-0687-0\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2015 DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-015-0843-1\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2016 DEGRO practical guidelines for radiotherapy of breast cancer VI: therapy of locoregional breast cancer recurrences. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-015-0939-7\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2018 Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1329-8\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2018 Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer.\u00a0<br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1270-x\">LINK<\/a><\/h4>\n<\/li>\n<li>\n<h4>2019 Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer : Indication and technical considerations. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-019-01507-9\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2019 Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO).\u00a0<br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-019-01495-w\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2019 Heart toxicity from breast cancer radiotherapy. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1378-z\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2020 Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review. <br \/><a href=\"https:\/\/doi.org\/10.1159\/000505656\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2021 Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients\u2014sequentially, or better simultaneously?\u00a0<br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-020-01667-z\">LINK<\/a><\/h4>\n<\/li>\n<li>\n<h4>2021 Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-020-01744-3\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2021 Long-Term Results of the TARGIT-A Trial: More Questions than Answers. <br \/><a href=\"https:\/\/doi.org\/10.1159\/000515386\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2022 DEGRO practical guideline for partial-breast irradiation. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-020-01613-z\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2024 DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-024-02202-0\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2024 Oligometastasis in breast cancer\u2014current status and treatment options from a radiation oncology perspective. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-022-01938-x\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2025 Regional nodal irradiation in breast cancer patients: A treatment planning study of the breast cancer working group of the German society of radiation oncology. <br \/><a href=\"https:\/\/doi.org\/10.1016\/j.meddos.2025.09.006\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2025 Implant-based reconstruction and adjuvant radiotherapy in breast cancer patients\u2014current status and DEGRO recommendations. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-024-02334-3\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2025 De-escalation strategies in early breast cancer: implications of sentinel lymph node biopsy omission for adjuvant radiotherapy. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-025-02391-2\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2026 DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer. <br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-025-02481-1\">LINK<\/a>\u00a0<\/h4>\n<\/li>\n<li>\n<h4>2026 DEGRO practical guidelines: radiotherapy of breast cancer\u2014regional nodal irradiation.\u00a0<br \/><a href=\"https:\/\/doi.org\/10.1007\/s00066-026-02554-9\">LINK\u00a0<\/a><\/h4>\n<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>\u00a02013 DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. LINK\u00a02014 DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast. LINK\u00a02014 DEGRO practical guidelines: radiotherapy of &hellip; <\/p>\n","protected":false},"author":8,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-49","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/pages\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":4,"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/pages\/49\/revisions"}],"predecessor-version":[{"id":177,"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/pages\/49\/revisions\/177"}],"wp:attachment":[{"href":"https:\/\/www.degro.org\/mammakarzinom\/wp-json\/wp\/v2\/media?parent=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}